On April 13, 2020 IntegraGen reported the company’s MERCURY cloud-based analytical software tool has achieved Conformité Européenne (CE) marking (Press release, Integragen, APR 13, 2020, View Source [SID1234556260]). This registration enhances the ability for IntegraGen sell MERCURY throughout the European Union (EU). MERCURY is utilized by researchers and clinicians to assist with the analysis of sequencing data derived from small and large gene sequencing panels as well as whole exome, RNA-Seq and whole genome sequencing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CE-IVD marking of MERCURY indicates that it meets the provisions of the Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. Click here to view MERCURY’s CE Declaration of Conformity certificate.

The cloud-based platform utilized by MERCURY also regularly undergoes independent verification of security, privacy, and compliance controls, achieving certifications in line with global standards. Learn more about how IntegraGen ensures the security and privacy of genomic data.